Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Penumbra Inc (PEN)

Penumbra Inc (PEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,361,569
  • Shares Outstanding, K 36,581
  • Annual Sales, $ 560,410 K
  • Annual Income, $ -15,700 K
  • 60-Month Beta 0.28
  • Price/Sales 18.13
  • Price/Cash Flow 519.94
  • Price/Book 15.07
Trade PEN with:

Options Overview Details

View History
  • Implied Volatility 42.85%
  • Historical Volatility 28.43%
  • IV Percentile 17%
  • IV Rank 7.74%
  • IV High 93.47% on 01/29/21
  • IV Low 38.60% on 09/10/21
  • Put/Call Vol Ratio 0.28
  • Today's Volume 41
  • Volume Avg (30-Day) 124
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 329
  • Open Int (30-Day) 544

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.16
  • Number of Estimates 3
  • High Estimate 0.27
  • Low Estimate 0.06
  • Prior Year 0.06
  • Growth Rate Est. (year over year) +166.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
259.74 +10.42%
on 08/23/21
293.20 -2.18%
on 09/16/21
+25.51 (+9.76%)
since 08/20/21
3-Month
243.79 +17.65%
on 08/11/21
293.20 -2.18%
on 09/16/21
+13.11 (+4.79%)
since 06/22/21
52-Week
163.49 +75.43%
on 12/16/20
320.00 -10.37%
on 05/05/21
+82.51 (+40.39%)
since 09/22/20

Most Recent Stories

More News
PEN INVESTOR NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Penumbra, Inc. Investors with Losses to Inquire About Class Action Investigation - PEN

/PRNewswire/ --

PEN : 286.76 (+1.24%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Penumbra, Inc. - PEN

New York, New York--(Newsfile Corp. - September 21, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc.("Penumbra" or the "Company") (NYSE: PEN). Such investors...

PEN : 286.76 (+1.24%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Penumbra, Inc. - PEN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN).  Such investors are advised to contact at  or 888-476-6529,...

PEN : 286.76 (+1.24%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Penumbra, Inc. - PEN

Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com...

PEN : 286.76 (+1.24%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Penumbra, Inc. - PEN

NEW YORK, NY / ACCESSWIRE / September 7, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE:PEN). Such investors are advised to contact...

PEN : 286.76 (+1.24%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Penumbra, Inc. - PEN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN). Such investors are advised to contact at  or 888-476-6529,...

PEN : 286.76 (+1.24%)
Penumbra, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

/PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 19th Annual Global Healthcare Conference on .

PEN : 286.76 (+1.24%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Penumbra, Inc. - PEN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN). Such investors are advised to contact at  or 888-476-6529,...

PEN : 286.76 (+1.24%)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Penumbra, Inc. (PEN) Investigation

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE:PEN). Investors...

PEN : 286.76 (+1.24%)
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Penumbra, Inc. Investors With Losses to Inquire About Class Action Investigation - PEN

WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Penumbra, Inc. (NYSE:PEN) resulting from allegations that...

PEN : 286.76 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

3rd Resistance Point 294.77
2nd Resistance Point 289.67
1st Resistance Point 286.46
Last Price 286.76
1st Support Level 278.15
2nd Support Level 273.05
3rd Support Level 269.84

See More

52-Week High 320.00
Last Price 286.76
Fibonacci 61.8% 260.21
Fibonacci 50% 241.74
Fibonacci 38.2% 223.28
52-Week Low 163.49

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar